Navigation Links
Novel protein complex enables survival in hostile environment

sulfide, an essential nutrient of M. jannaschii.

This enzyme, coenzyme F420-dependent sulfite reductase, or Fsr, "uses an unusual coenzyme ?a deazaflavin molecule called Factor 420 -- as an electron carrier for the reduction of sulfite. None of the previously described sulfite reductases use F420," Johnson said.

By use of genome-sequence-driven proteomics techniques, they identified the gene for the enzyme. A search showed that this gene exists only in hydrothermal vent methanogens and their close relatives, but not in other microorganisms.

From the sequence of the fsr gene, Johnson and Mukhopadhyay discovered that the novel activity of Fsr comes from a unique structure; two previously known proteins with unrelated functions have been physically combined by use of a linker. Even after this linking, the two units retain their individual characteristics.

"We hypothesize that the NH2-terminal half of Fsr (named Fsr-N) collects electrons via F420 and the COOH-terminal half (Fsr-C) uses those electrons to reduce sulfite to sulfide," Johnson said.

In their experiments, the researchers detected both of these individual properties as well as the combined activity. "Fsr-N resembles a protein that introduces electrons into the membrane-based energy transduction systems of certain archaea. Such an energy transduction system is also found in E. coli and humans," Mukhopadhyay said. "Fsr-C is similar to the sulfite reductases that are found in certain bacteria and archaea. These previously described sulfite reductases do not use coenzyme F420 as the electron source and are also not tethered to their electron-donating partners."

"The existence of Fsr poses several questions that are important in the context of evolution of metabolism and enzyme mechanism," Mukhopadhyay said. "We do not know whether the splitting of the fsr gene gave rise to the sulfite reductases of the bacteria and energy transducers of certain archaea or if
'"/>

Source:Virginia Tech


Page: 1 2 3 4 5

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Novel live reporting system to track cells
11. Field of beams - Novel system uses polarized light pulses to reveal crop health
Post Your Comments:
(Date:12/15/2009)... devastating brain diseases such as Alzheimer,s and Parkinson,s, doctors ... to help a patient. , But they come up ... of patients with ataxia disabling disorders that rob ... Florida neurologists are trying to change that with the ... National Institute of Neurological Disorders and Stroke to establish ...
(Date:12/15/2009)... woolly mammoths and ancient American horses may have ... thousand years longer than previously thought. After plucking ... a team of researchers used cutting-edge techniques to ... permafrost samples dated to between 7,600 and 10,500 ... least one population of these now-extinct mammals endured ...
(Date:12/15/2009)... Rip currents exact an enormous emotional and economic toll on ... drown in rip currents each year in U.S. waters and ... thousand deaths worldwide. A serious disconnect exists between rip ... confused with rip tides and undertows, and more importantly, most ... escape, from a rip current. , The goal of the ...
Breaking Biology News(10 mins):UF to lead national effort to help patients with rare brain disease 2UF to lead national effort to help patients with rare brain disease 3Late-surviving megafauna exposed by ancient DNA in frozen soil 2Late-surviving megafauna exposed by ancient DNA in frozen soil 3Late-surviving megafauna exposed by ancient DNA in frozen soil 4WorldHeart Signs Agreements for Next Generation Minimally Invasive Blood Pump 6327 1WorldHeart Signs Agreements for Next Generation Minimally Invasive Blood Pump 6327 2WorldHeart Signs Agreements for Next Generation Minimally Invasive Blood Pump 6327 3Pioneer 28R 29 Surgical Technology Inc and Bonovo 28R 29 Orthopedics Inc Establish Foothold in Fastest Growing Spine Market in the World 6325 1Pioneer 28R 29 Surgical Technology Inc and Bonovo 28R 29 Orthopedics Inc Establish Foothold in Fastest Growing Spine Market in the World 6325 2China Sky One Medical Inc Announces Record Third Quarter 2009 Results 6323 1China Sky One Medical Inc Announces Record Third Quarter 2009 Results 6323 2China Sky One Medical Inc Announces Record Third Quarter 2009 Results 6323 3China Sky One Medical Inc Announces Record Third Quarter 2009 Results 6323 4China Sky One Medical Inc Announces Record Third Quarter 2009 Results 6323 5China Sky One Medical Inc Announces Record Third Quarter 2009 Results 6323 6China Sky One Medical Inc Announces Record Third Quarter 2009 Results 6323 7China Sky One Medical Inc Announces Record Third Quarter 2009 Results 6323 8China Sky One Medical Inc Announces Record Third Quarter 2009 Results 6323 9China Sky One Medical Inc Announces Record Third Quarter 2009 Results 6323 10
... Africa's past and future climate shows that the Sahel ... the 1990s, could experience wetter monsoons for decades to ... intensify further. Oceanic warming consistent with an increase in ... expected 21st-century changes to Africa's monsoons. , James Hurrell ...
... right whales, found during the summer in Alaska waters, is ... world. Commercial whaling in the 1800s has now left us ... recognized as a different species from right whales seen in ... To help define areas and ecological parameters critical to the ...
... South Korean team announced last week that it had ... that were genetically matched to specific people. But their ... Yuri Verlinsky of the Reproductive Genetics Institute, based in ... without resorting to therapeutic cloning. "It would be a ...
Other Biology News:Africa to take it on chin again with climate change 2Africa to take it on chin again with climate change 3Habitat use by North Pacific right whales, Eubalaena japonica, in the Bering Sea and Gulf of Alaska 2Double triumph in stem cell quest 2Double triumph in stem cell quest 3Double triumph in stem cell quest 4
(Date:12/16/2009)... LAS VEGAS, Dec. 16 Cord Blood ... cord blood stem cell preservation company ( http://www.cordblood-america.com ... potential of stem cells, a biological insurance policy, ... it has reduced its debt by a total ... quarter of 2009 and total debt eliminated for ...
(Date:12/16/2009)... Protocol Assessment with the Food and Drug ... - AEterna Zentaris Inc. (NASDAQ: AEZS ... biopharmaceutical company focused on oncology and endocrine ... partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), ... for perifosine (KRX-0401), the Company,s PI3K/Akt pathway ...
(Date:12/15/2009)... Epeius Biotechnologies Corporation, an emerging leader in the ... of the cutting-edge science behind its lead oncology ... world rediscovered the Cyclin G1 gene ... and disease progression, and thus a prime target ... National Cancer Institute investigating the role of microRNAs ...
(Date:12/15/2009)... Aethlon Medical, Inc. (OTC Bulletin Board : AEMD) ... Wayne Comper have joined the Science ... Dr. Schorey and Dr. Comper are leading researchers ... subsidiary of Aethlon Medical, was recently formed to ... device being advanced as an adjunct therapy for ...
Breaking Biology Technology:Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5
... debentures of Victhom , to be completed by ... - Victhom Human Bionics Inc. ("Victhom", TSX: VHB) ... today the execution on April 29, 2009 of ... to develop and commercialize products currently being developed ...
... 26 percent in first quarter of 2009 compared to ... CRY ) , an implantable biological medical device ... for the first quarter of 2009 increased 4 percent ... to $25.6 million for the first quarter of 2008.Operating ...
... VANCOUVER, April 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... financial results for the first quarter ended March 31, ... for our first quarter in what has been a ... Hunter, President and CEO of Angiotech. "Sales in our ...
Other Biology Technology:Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities 2Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities 3Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities 4Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities 5CryoLife Reports Record First Quarter Revenues of $26.7 Million 2CryoLife Reports Record First Quarter Revenues of $26.7 Million 3CryoLife Reports Record First Quarter Revenues of $26.7 Million 4CryoLife Reports Record First Quarter Revenues of $26.7 Million 5CryoLife Reports Record First Quarter Revenues of $26.7 Million 6CryoLife Reports Record First Quarter Revenues of $26.7 Million 7CryoLife Reports Record First Quarter Revenues of $26.7 Million 8CryoLife Reports Record First Quarter Revenues of $26.7 Million 9CryoLife Reports Record First Quarter Revenues of $26.7 Million 10Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 21
... Microarrays designed for immunological studies, ... on the flexible and powerful Paraflo ... are available as part of our ... Custom Probe Content Probe ...
... of Molecular Imaging (MI) Software for use ... research and drug discovery applications. The Regulatory ... and Drug Administrations Code of Federal Regulations ... Signatures [21 CFR Part 11]. KODAK MI ...
... Select Tissue Arrays are intended for laboratory ... were fixed in neutral buffered formalin and ... diagnosis was performed by certified pathologists. ... blocks and relocated into a new recipient ...
... industry standard microarray image analysis software because ... analysis tools, visualizations, automation capabilities, performance and ... with every GenePix scanner, and it also ... all types of arrays. A wide range ...
Biology Products: